Brief reportsEnhanced early inhibition of platelet aggregation with an increased bolus of tirofiban☆
Section snippets
Acknowledgements
We thank Barbara McVan, RN, Patricia Q. Baumann, MS, Michaeleanne Rowen, RN, Danielle C. Tardiff, RN, Shiv Kapoor, PhD, Jaromir Bobek, MS, Debbie Regan, RN, and Cyndi Dietrich, MS, without whom completion of the studies would not be possible.
References (10)
- et al.
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting
J Am Coll Cardiol
(2001) - et al.
Suboptimal early inhibition of platelets by treatment with tirofibanimplications for coronary interventions
Am J Cardiol
(2002) - et al.
Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina and non–Q-wave myocardial infarction undergoing percutaneous coronary intervention
Am J Cardiol
(2002) - et al.
American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)
J Am Coll Cardiol
(2001) - et al.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
N Engl J Med
(2001)
There are more references available in the full text version of this article.
Cited by (70)
Intracoronary high-dose bolus tirofiban administration during complex coronary interventions: A United States-based case series
2018, Cardiovascular Revascularization MedicineCitation Excerpt :These studies demonstrated an acceptable 30-day safety profile between the IC and IV routes of administration. In the majority of these cases, the 10 mcg/kg bolus was used, which has been proven to provide inadequate platelet aggregation inhibition [36,37]. There are only three randomized control studies investigating the use of the current FDA-recommended high dose bolus (HDB) regimen of 25 mcg/kg tirofiban.
The role of Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and the interference with anemia
2016, International Journal of CardiologyThe Role of Tirofiban in Percutaneous Coronary Interventions and Primary Angioplasty
2011, Revista Espanola de Cardiologia SuplementosAntiplatelet therapies and the role of antiplatelet resistance in acute coronary syndrome
2009, Thrombosis ResearchThe Role of Tirofiban in Percutaneous Coronary Interventions and Primary Angioplasty
2011, Revista Espanola de Cardiologia SuplementosAn Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives
2023, High Blood Pressure and Cardiovascular Prevention
- ☆
This study was supported by Merck & Company, Inc., West Point, Pennsylvania.
Copyright © 2002 Excerpta Medica Inc. All rights reserved.